Although the field of human genetics has provided a promising approach to identify the key pathways that lead to immune-mediated diseases, until recently most of the discoveries in this area have been limited to disorders that are caused by deleterious mutations in single genes 1 . Genomic regions that contain the causal gene for a monogenic disorder can be identified using family-based linkage studies, owing to the strong penetrance of these mutations. When similar study designs were used to identify genes that are involved in the predisposition to more common immune-mediated diseases, such as Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE) and type 1 diabetes, success was limited. These difficulties were due to the fact that such diseases can involve multiple different genetic risk factors and that non-genetic risk factors can also have a role. Consequently, each individual risk factor confers a more modest risk than in the case of a single gene that causes a monogenic disease.
Powerful association-based approaches test the causal genetic variation more directly than linkage analyses 2 and they are therefore more useful for detecting individual risk factors that confer only a moderate risk. Initially, association-based genetic studies were generally limited to the testing of relatively small cohorts of patients with a small number of genetic variants in one gene or in a small number of genes. Unfortunately, this approach led to a large number of false-positive reports 3 . This outcome was not that surprising given the low probability that an investigator could select the few causal genes from the human genome, even armed with the best knowledge of disease pathogenesis.
The key to improving this approach was to probe the entire genome, as had been done in linkage analysis, but with the statistical power of an association study. In contrast to a typical genome-wide linkage scan that analyses a relatively small number (300-5,000) of genetic markers, it was predicted that a genome-wide association (GWA) study would probably require typing of ~500,000 genetic markers, known as singlenucleotide polymorphisms (SNPs), owing to the low level of linkage disequilibrium expected for the human genome 4 . However, at the time that this prediction was made, the most comprehensive SNP map of the human genome only contained ~2,000 SNPs 5 . Since then, substantial efforts have been made to catalogue and map the correlation patterns of SNPs (known as haplotypes) to facilitate genetic studies of human disease. Specifically, the International HapMap Project has catalogued the haplotype patterns across the human genome by analysing more than three million SNPs, and has created a public resource to provide researchers with easy access to the data regarding a gene of interest or for the entire genome (see the International HapMap website) 6 . In addition, while these efforts were ongoing, there was a commercial effort to develop platforms that would allow the testing of hundreds of thousands of SNPs in a single genotyping reaction. These technological platforms have
Tag SNPs
Representative SNPs in a region of the genome with high linkage disequilibrium. Tag SNPs allow a reduction in the number of SNPs that must be genotyped while allowing the generation of the same amount of information. The HapMap Project catalogued tag SNPs in the entire genome.
progressed over time and now have the ability to type ~1,000,000 SNPs in parallel.
These advances have enabled many GWA studies of immune-mediated diseases in moderately sized cohorts. Specifically, in the past 12-18 months, numerous studies of 500-2,000 cases and equivalent numbers of unrelated control subjects have been published for many of the diseases mentioned earlier. Have these GWA studies led to new discoveries as hoped? The answer to that question is emerging as a resounding 'yes' . The GWA studies carried out so far have revealed new pathways that contribute to disease development and have also identified common genes among immune-mediated diseases that had not previously been identified. This review aims to provide information that will allow immunologists to understand the rapid conceptual and technological changes that have enabled GWA studies, and to provide some of the tools that are necessary to overcome the challenges and take advantage of the strengths of these types of study. Furthermore, we attempt to provide some insight into how these discoveries could influence the path of both basic and clinical immunology research.
Understanding GWA studies To interpret the results of GWA studies that investigate common diseases, it is important to have an understanding of the underlying genomic context. The human genome consists of approximately three billion base pairs and approximately ten million positions in this genetic code are polymorphic in the human population at a significant frequency 7 . It is these sequence differences that result in phenotypic differences such as height, skin colour and differential resistance to infection or disease. Some of this variation is neutral, some is advantageous and some is disadvantageous to an individual's health, and this can be context dependent. Therefore, such genetic variation can be considered part of the normal variation that occurs in a species. The challenge is then to determine, in a timeand cost-efficient manner, which of the common variants contribute to disease susceptibility.
Although testing all known genetic variants in an association study would be the most direct approach, this is currently too costly and is not necessary, given the structure of genetic variation in the human genome. Specifically, the information generated by the International HapMap Project details the correlation pattern between the SNPs contained in the human genome. In cases where two or more SNPs are highly correlated, it is only necessary to test one of the SNPs, as this information will provide equivalent genetic information on the other SNPs that are part of the correlated group 6, 8 . GWA studies are therefore based on the concept that by testing a large number of SNPs it will be possible to detect disease-causing alleles, either by testing the actual causal variant or a SNP that is correlated with it.
Commercial genotyping chips have progressively increased the number of SNPs that can be typed in a single experiment
. Moreover, these highly parallel genotyping platforms have also begun to incorporate structural variants known as copy-number variants 9 . Testing such a large number of variants can give rise to a large number of false-positive results, and therefore it is crucial to conduct a sufficiently powerful study and to carry out rigorous quality-control analyses on the genotype data before association testing [10] [11] [12] 
. In addition, it is important to carry out replication studies to distinguish the false-positive results from the true positives 13 . The results of replication studies should be consistent (that is, finding repeated associations to the same allele) and reported for the same phenotypes to constitute true validation 13 . one of the first successful GWA studies, in which ~100,000 SNPs in 96 cases and 50 control subjects were typed, Box 1 | Genome-wide association study genotyping platforms
In recent years, two technologies have shared the market of genome-wide association (GWA) studies: Affymetrix GeneChips and Illumina BeadChips. Both platforms use the same basic principle of hybridization of genomic DNA fragments to a fixed probe. In the case of the Affymetrix GeneChip, labelled DNA is hybridized to millions of probes synthesized on a 1.5 cm by 1.5 cm glass plate. For the Illumina Infinium assay, genomic DNA is hybridized to probes fixed on 3 µm silica beads that self-assemble in microwells on planar silica slides. Allelic specificity is conferred by enzymatic-based extension and the labelling of the additional nucleotide. These microarray technologies require 250-750 ng of genomic DNA per sample and one sample is simultaneously tested for all markers. The Affymetrix standard workflow is 5 days, whereas the Illumina workflow is 3 days.
Since the first of the GWA studies that used single-nucleotide polymorphisms (SNPs) in 2004, Affymetrix and later, Illumina, developed numerous chips that were increasingly powerful for capturing genomic variability (see the table for A fundamental principle in genetics stating that the genotypic frequencies of a large, randomly mating population remain constant in the absence of mutation, migration, natural selection or random drift.
Penetrance
The probability, under given environmental conditions, with which a specific phenotype is expressed by individuals with a specific genotype. For example, if 50% of the people with a gene 'X' that is known to cause a disease do in fact develop the disease, then the penetrance of that gene is 0.5.
Genome-wide linkage scan
A linkage study carried out with markers located across the entire genome. Linkage studies were traditionally carried out with ~300 markers of simple sequence-length repeats and more recently with ~5,000 single-nucleotide polymorphisms.
Genetic markers
Genomic variants used as positional tools to find associations between specific DNA fragments and a certain phenotype or disease.
Single-nucleotide polymorphisms
(SNPs). Genomic variants in which a single base in the DNA differs from the usual base at that position. SNPs are the most common type of variation in the human genome.
Linkage disequilibrium
A situation in which alleles in a chromosomal region occur together more often than can be accounted for by chance, indicating that the alleles are in close proximity on the DNA strand and are most likely to be passed on together within a population.
Haplotype
A combination or pattern of alleles at multiple linked loci that are inherited together.
identified a polymorphism in the gene encoding complement factor H that confers a risk for age-related macular degeneration 14 . Since then, there have been numerous studies carried out to identify risk factors for coeliac disease, Crohn's disease, multiple sclerosis, rheumatoid arthritis, SLE, type 1 diabetes and many other complex immune-mediated diseases [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] (TABLE 1) .
The unbiased nature of GWA studies is evident from some of the gene discoveries that are summarized in TABLE 1. For example, two genes that have recently been shown to have a role in autophagy were identified by GWA studies looking at susceptibility to Crohn's disease 19, 20 , although a role for autophagy in Crohn's disease had not previously been appreciated. In addition, it is exciting that comparing the results from the study of one disease to those from the study of another can reveal common risk factors that influence susceptibility to more than one disease. A striking example of this is the finding that a ~500-kb genomic region on chromosome 4q27 that contains the genes encoding interleukin-2 (IL-2) and IL-21 is associated with susceptibility to coeliac disease, multiple sclerosis, rheumatoid arthritis and type 1 diabetes 24, 26 .
It should be noted, however, that even when statistically significant associations are identified, GWA studies do not always identify the causal gene in an associated region. This might be due to the fact that the associated region contains more than one gene (as in the previous example) or does not contain any known coding sequence (also known as a gene desert). An example of a gene desert is the association of Crohn's disease with a region of chromosome 5p13 (REF.15) ; although this genomic region is strongly associated with disease susceptibility, it contains no known genes. Further investigation led researchers to propose that the underlying mechanism of action of this associated region in Crohn's disease was through differential expression of the nearby prostaglandin E receptor 4 (PTGER4) gene. These results indicate that functional studies are often necessary to elucidate the biological mechanisms by which an associated region confers disease susceptibility 15 . It should also be noted that, even when the association and linkage disequilibrium results point to a single causal gene, the causal sequence variant is not always easy to identify.
Box 2 | Statistical analyses of genome-wide association study data
Association studies are increasingly carried out in the context of unbiased genomewide approaches. The technologies used, such as microarrays, allow for numerous assays to be carried out simultaneously. A fraction of the single-nucleotide polymorphisms (SNPs) will perform suboptimally under these uniform conditions and can generate unreliable data. Therefore, steps of quality control and replication are used to ensure the validity of the results. The figure illustrates the steps involved in a typical association study, using as an example the Wellcome Trust Case Control Consortium (WTCCC) genomewide association (GWA) studies of seven complex diseases and the following replication for the SNPs associated with Crohn's disease 16, 19 . The first step (the screen) is carried out on a first cohort of cases and matched controls and/or family-based trios. This initial genotyping is followed by careful quality control steps to identify problematic SNPs (such as SNPs not in Hardy-Weinberg equilibrium) or DNA (such as DNA that appears to be contaminated by other samples). Low-quality markers and samples are rejected. The association tests are then carried out on the clean dataset. In addition, poor matching between cases and controls or the presence of genetically distinct subpopulations among the studied samples -a phenomenon called stratification -can give rise to false association signals. Stratification must be tested and can then be used to calculate a correction factor that is applied to the association results.
Following the screen, a threshold of significance is chosen for the inclusion of markers in the replication step (Step 2). The replication markers are typed in a second, independent cohort. A quality control step is also applied to these data and appropriate correction factors are applied to the results. A true association signal is confirmed by the detection of a significant association in both screening and replication steps. Furthermore, this association has to be in the same direction (that is, the same allele has to be associated in both steps). Given the large number of hypotheses tested in GWA studies (each SNP tests a different hypothesis), a strict threshold is necessary to minimize the number of false positives that are reported, and the significance threshold of p<5x10 -7 is becoming accepted 16 . 
Genotyping
A test designed to identify the genetic constitution of an individual -that is, the alleles present at one or more specific loci.
Alleles
Alleles are alternative forms of genes that are located at a specific position on a specific chromosome. In association studies, the term allele is most commonly used to refer to one variant of a marker.
Causal variant
The specific DNA sequence that functionally gives rise to the increased risk conferred by the causal gene or genomic region identified by an association.
Copy-number variant
(CNV). A genomic variant characterized by differences in the number of copies of specific repeated DNA fragments that range from 1 kb to several Mb long. CNVs can contain entire genes and can be used as markers in association studies.
Association testing
A statistical approach that tests for association between marker or candidate gene alleles and diseases. If a correlation is observed between genotype and phenotype, there is said to be an association between the marker or allele and the disease or trait.
Replication studies
Studies designed to test (or replicate) a prior and explicit genetic hypothesis. For example, replication studies are carried out to validate the findings of a genome-wide association study, thereby discriminating false positives from true positives identified in the study.
In summary, not all identified and confirmed associations lead to the immediate identification of the causal gene and/or the causal variant. one feature that is true of all the variants that have been identified so far for common diseases is that the risk imparted by each of them is relatively modest -odds ratios usually range from 1.1 to 1.4 (TABLE 1) . Analogous to the situation for non-genetic risk factors (such as the contribution of smoking to the risk of lung cancer), no single genetic risk factor can determine whether an individual will develop a disease; each variant can only modulate an individual's probability of developing disease. Furthermore, although the first GWA studies have greatly increased the number of known genetic risk factors (for example, studies of Crohn's disease have increased the number of known risk factors from 2 to 32 genes between 2001 and 2008), it is important to recognize that many more remain unknown. Despite this incomplete picture, these discoveries have identified many new pathways that contribute to disease pathogenesis 27 .
GWA studies reveal new pathways to disease Chronic immune-mediated diseases affect approximately 3-5% of the population worldwide 28 . Most of the current therapies for such diseases rely on nonspecific immunosuppressive approaches, in part owing to our relative lack of knowledge of the specific mechanisms that cause disease onset and progression. Excitingly, the recent explosion in GWA studies has had a marked effect on our ability to catalogue the true genetic risk factors for many of these diseases. Although we are still in the early stages of GWA studies, in the following sections we highlight some of the key findings of this approach in investigating the genetics of Crohn's disease, multiple sclerosis, rheumatoid arthritis and SLE, and we discuss how these studies have shed light on new pathways that might be potential therapeutic targets.
Crohn's disease. Crohn's disease and ulcerative colitis are debilitating, inflammatory diseases of the gastrointestinal tract, collectively known as the inflammatory bowel diseases (IBDs). Genetic studies have been particularly successful in the identification of risk factors for Crohn's disease. In 2001, one of the first discoveries of a causal gene for a complex trait was the identification of three genetic variants in the nucleotide-binding oligomerization domain protein 2 (NOD2) gene that were associated with Crohn's disease 29, 30 . A second discovery came just a few months later with the identification of a haplotype, known as IBD5, of multiple genetic variants in a region that contains five genes: interferon-regulatory factor 1 (IRF1), solute-carrier family members SLC22A5 and SLC22A4, PDZ-and LIMcontaining protein 4 (PDLIM4) and prolyl-4 hydroxylase (P4HA2) 31 . These discoveries were made using the traditional approach of genome-wide linkage analysis followed by association mapping of linked regions that had previously been so successful in the study of single-gene disorders.
Although the difficulties encountered in the identification of the causal gene for the IBD5 haplotype foreshadowed some of the challenges that lay ahead, it was widely felt that association studies that targeted linkage regions or candidate genes would continue to reveal the key pathways that could influence susceptibility to Crohn's disease. However, no further genes linked to Crohn's disease were identified in the following 5 years. During that period, functional studies of NoD2 clearly indicated a central role for this protein in mediating interactions between microorganisms and the intestinal mucosa and indicated that causal alleles might shift the balance in a way that could allow minimally invasive bacteria to trigger the onset of Crohn's disease [32] [33] [34] ( FIG. 1) .
Such bacteria normally adhere to the intestinal epithelial lining but, under conditions of tissue damage and/or due to host defects in clearing the bacteria, they can invade the cells of the host epithelium, thereby disrupting normal immune homeostasis in the gut.
The first four GWA studies that investigated Crohn's disease using 300,000 or more SNPs were carried out by the North American National Institute of Diabetes, Digestive and Kidney diseases (NIDDK) IBD Genetics Consortium, a Belgian-French group, and the Wellcome Trust Case Control Consortium (WTCCC), and they led to the identification of a total of eight novel genetic risk factors 15, 16, 18, 20 (TABLE 1) . This windfall in the discovery of multiple disease genes was more than had previously been identified for any other immune-mediated disease and it had a marked effect on our understanding of the different pathways that are involved in IBD susceptibility and/or pathogenesis.
one of the most unexpected findings to have come from the Crohn's disease GWA studies is that autophagy has an important role in disease pathogenesis. This is supported by the finding that two genes that are involved in autophagic processes -autophagy 16-like 1 (ATG16L1) and immunity-related GTPase family member M (IRGM) -were significantly associated with disease in GWA studies 19, 20 . recent studies have shown broad roles for autophagy in tumour suppression, organ development, neurodegeneration, innate immune responses, antigen presentation, T-cell homeostasis and the clearance of intracellular microorganisms 35 . In yeast, more than 30 genes required for autophagy have been identified, and the molecular cascade that regulates autophagy has recently been comprehensively reviewed 36 . The NIDDK study identified a non-synonymous amino-acid change of alanine to threonine at position 197 (A197T) in ATG16L1 that was associated with Crohn's disease, a finding that was reported in an independent association study of non-synonymous coding SNPs 20, 37 . The NIDDK study suggested that the mechanism by which genetic variants of ATG16L1 affect Crohn's disease pathogenesis might be through alterations in the sensing and clearance of gut microflora (FIG. 1e) . Specifically, knock-down experiments in human cervical carcinoma cells (HeLa cells) indicated that ATG16L1 is essential for the normal formation of autophagosomes after exposure to stimuli that are known to trigger autophagy, such as serum starvation, rapamycin or intracellular bacterial Nature Reviews | Immunology 
Gene desert
A large genomic segment devoid of genes. Gene deserts tend to harbour limited sequence conservation. The rare conserved region can contain transcriptional regulatory elements.
Odds ratios
Measures of relative risk, usually estimated from studies that compare patients with control subjects. In a genetic disease context, the odds ratio is defined as the ratio of the odds of having an allele or a genotype while being affected by the disease to the odds of having the same allele or a genotype while being a healthy control. . Apart from this single study, and the fact that ATG16L1 has been shown to form a trimolecular protein complex with ATG5 and ATG12, little is known about the role of ATG16L1 in autophagy and other cellular processes. Given that ATG5 is known to be required for lymphocyte development and signalling, and in particular for the maintenance of innate immune B-1 cells in peripheral tissues, it is probable that ATG16L1 has multiple functions in the immune system 6, 38 . In addition to defence against pathogens, autophagic vacuoles might allow some bacterial and viral pathogens to establish a replicative niche and supply them with nutrients for growth 39 . As both excessive and defective autophagy could have deleterious effects, future studies should focus on the functional consequences of ATG16L1 variants associated with Crohn's disease in a cell-and tissue-specific context. Currently, even less is known about IRGM, another autophagy-related gene that was associated with Crohn's disease in the WTCCC study 16 . The authors localized the disease association to the IRGM gene but, in the re-sequencing analyses, they could not identify the causal variant in patients 19 . In humans, the IrG gene family consists of two members, IRGM and IRGC. In contrast to the structural diversity of IrG proteins in mice, the human IrG proteins lack most of the N-and C-terminal domains that flank the GTP-binding domain and the promoter lacks an interferon (IFN)-response element that is found in mouse IrG genes 40 . In addition, human IrGM has many splice variants, although their cellular distribution and biological function are unknown 41 . Studies that show a role for human IrGM protein in the resistance to mycobacterial infection indicate that the human protein probably has an immune function. Although its exact role in the pathogenesis of Crohn's disease remains to be determined, it is probable that, together with ATG16L1, IrGM influences the host immune response to the gut microflora 42 (FIG. 1e) . In addition to the data indicating that aberrant autophagic processes contribute to Crohn's disease through abnormal handling of the gut microflora, the multiple genes that have been identified in GWA studies of Crohn's disease have further indicated that dysregulation of the innate immune system could have a dominant role in determining disease susceptibility. For example, the neutrophil cytosolic factor 4 (NCF4) gene was found to have a significant association with susceptibility to Crohn's disease in the NIDDK study, which supports this theory. NCF4 encodes the p40PHoX protein, which has previously been shown to have an important role in NADPH oxidase activity and the production of reactive oxygen species after phagocytosis, both of which are important for mounting effective antimicrobial immune responses 20, 43, 44 . Moreover, the WTCCC study identified a region of ~1 Mb on chromosome 3p that was associated with susceptibility to Crohn's disease and contained multiple genes. This region was found within the IBD9 locus (which spans ~25 Mb) that had previously been identified in early linkage studies of IBD 45, 46 . Although the WTCCC study did not identify the causal gene in this region, a more recent study found a coding variant (r689C) in the macrophage-stimulating 1 (MST1) gene (which encodes macrophage-stimulating protein, MSP) that might explain the WTCCC results 46, 47 . It has been suggested that the r689C variant might influence the production of pro-inflammatory mediators such as nitric oxide, prostaglandin E2 (PGE2) and IL-12p40 in response to lipopolysaccharide or cytokine-mediated macrophage activation 47 (FIG. 1f) .
B-1 cells
Interestingly, the results of another recent independent study indicate that variation in the gene encoding the receptor for MSP might also influence susceptibility to Crohn's disease 48 . It is tempting to conclude from these studies that Crohn's disease is uniquely caused by disturbances in key pathways of the innate immune system; however, the adaptive immune system clearly also has an important role in disease susceptibility and/or pathogenesis. The most striking example is that of IL-17-producing CD4 + T helper cells (T H 17 cells). The first genetic evidence that T H 17 cells might be involved in human inflammatory diseases came from the report of an association of IL23R with Crohn's disease in the NIDDK GWA study 18 . It is thought that IL-23 is an important growth factor for T H 17 cells, and the NIDDK study showed that the glutamine allele at residue 381 in the IL-23r protein conferred significant protection against developing Crohn's disease. The more common allele at position 381 is an arginine residue (occuring at a frequency of ~95%), which is highly conserved across multiple species, including the opposum 18 . Although functional studies aimed at determining the mechanistic impact of the glutamine allele at residue 381 are ongoing, it is interesting to note that this genetic variant also had a similar protective effect in a psoriasis cohort, which is consistent with the clinical observation that psoriasis and Crohn's disease frequently occur together 49 .
IL-23 is a heterodimeric cytokine composed of linked p19 and p40 subunits that is produced by a broad array of cells, including dendritic cells (DCs) and macrophages 50 . Many microbial signals, such as Toll-like receptor (TLr) ligands, LPS and the synthetic rNA mimic polyI:C, increase the expression of IL-23 subunits, resulting in the production of bioactive cytokine in the setting of mucosal disruption (FIG. 1b) . In response to IL-6 and transforming growth factor-b (TGFb), naive CD4 + T cells upregulate the expression of IL-23r, providing a positive autocrine signal for the proliferation of T H 17 cells. However, little is known so far about the IL-23r signalling pathways that control human T H 17-cell differentiation and function in models of autoimmunity 51 . A recent report by Annunziato et al. showed that two populations of T H 17 cells are found in patients with Crohn's disease: one subset is characterized by the expression of CC-chemokine receptor 6 (CCr6), IL-23r and retinoic-acid-receptor-related orphan receptor gt (rorgt; a transcription factor important for T H 17-cell differentiation) and the second subset is characterized by the production of IFNg (REF. 52 ).
It is noteworthy that CCr6-expressing T H 17 cells are recruited to inflamed joints in rheumatoid arthritis through the production of CC-chemokine ligand 20 (CCL20) and contribute to disease pathogenesis. However, there is currently no genetic evidence for an association of genes involved in T H 17-cell biological pathways with rheumatoid arthritis 53 . Future studies should aim to elucidate the precise functional defects that are associated with the heterogeneous populations of T H 17 cells in the pathogenesis of Crohn's disease and other immune-mediated diseases, and to address the functions of these cell populations in patients carrying genetic variants associated with disease susceptibility.
Multiple sclerosis.
Multiple sclerosis is an autoimmune disorder characterized by inflammation, demyelination and axonal degeneration in the central nervous system. Decades of studying the cellular and molecular immunology of patients with multiple sclerosis and of analysing experimental disease models have shown that cytokines and adaptive immune responses are involved in disease pathogenesis. Despite this knowledge, the only known genetic risk factors for multiple sclerosis that had been identified before GWA studies were those found in the MHC locus 54 . A recent GWA study of patients with multiple sclerosis indeed showed the existence of causal genetic variation in genes encoding cytokine receptors and molecules associated with adaptive immunity. Specifically, the first GWA study of multiple sclerosis, which was carried out by the International Multiple Sclerosis Genetics Consortium (IMSGC) 21 , showed that the MHC locus had the strongest genetic effect in this study. In addition, this study showed that disease was also associated with the genes encoding the IL-7r α-chain (IL7RA) and IL-2r α-chain (IL2RA). The reported association between IL7RA and multiple sclerosis was supported by two other independent studies 55, 56 . IL-7 has previously been shown to be important for homeostasis of the memory T-cell pool and might have a role in promoting the proliferation of autoreactive T cells in patients with multiple sclerosis 21 In one of these studies, the authors offered a mechanistic insight into the function of the non-synonymous polymorphism T244L in IL7-rA. In vitro studies indicated that differential splicing of IL7RA changed the ratio of the soluble form of the IL-7rA protein to the membrane-bound form, which could lead to compromised immune responses to multiple-sclerosis-related antigens 55 . By contrast, the causal variation in IL2RA that leads to multiple sclerosis has not yet been identified. It is notable, however, that IL2RA is also associated with type 1 diabetes, providing support for the concept that genetic risk factors can either be disease specific or common to multiple related diseases, and providing a rationale for examining the functional consequences of associated genetic variants in different phenotypic contexts 21, 57 . Taken together, these data support the long-held view that the regulation of expression of some interleukins and/or their receptors is of central importance in the pathogenesis of multiple sclerosis. Importantly, these studies were successful in pinpointing the specific factors that are involved in disease pathogenesis and indicate that an increased knowledge of alternative splicing events could be crucial in understanding susceptibility to immune-mediated diseases.
Rheumatoid arthritis. rheumatoid arthritis is a common autoimmune disease characterized by chronic, destructive and debilitating inflammation of the joints. Two recent GWA studies, which have shown that genomic regions on chromosomes 6q23 and 9q33.2 are specifically associated with rheumatoid arthritis 22, 58 . Examination of the 6q23 locus revealed that the tumour-necrosis factor-α (TNFα)-induced protein 3 (TNFAIP3) gene is located in this associated region. TNFAIP3 acts as a checkpoint in TNF-induced nuclear factor-κB (NF-κB) activation and has both ubiquitin-ligase activity and deubiquitylating activity specific for molecules in the TNF-receptor (TNFr) signalling pathways 16, 58 . Although a causal variant that formally implicates TNFAIP3 in the pathogenesis of rheumatoid arthritis has not yet been identified, it is hoped that re-sequencing and subsequent association analyses will identify a causative, non-synonymous SNP or a regulatory SNP that alters the expression of TNFAIP3.
The associated SNP in the 9q33.2 region was found to be in linkage disequilibrium with two genes that are also relevant to chronic inflammation: TNFr-associated factor 1 (TRAF1) and complement component 5 (C5). Although complement activation in a chronic inflammatory disease such as rheumatoid arthritis is likely, it is probable that the causal gene in the TRAF1-C5 locus is TRAF1. TrAF1 is not only thought to be a negative regulator of TNFr and T-cell receptor (TCr) signalling, but is also known to bind TNFAIP3 (REFS 59, 60) . Taken together, the evidence that TNFAIP3 and TRAF1 are the probable causative genes in the 6q23 and 9q33 chromosomal regions supports an important role for TNF-mediated pathogenic mechanisms in rheumatoid arthritis, a hypothesis that is consistent with the fact that anti-TNF biologicals are currently the most effective therapies for the disease 61, 62 . In addition to the identification of the above risk factors by GWA studies, a recent candidate-gene association study identified that genetic variation surrounding the signal transducer and activator of transcription 4 (STAT4) gene is also associated with rheumatoid arthritis 63 . It has been shown that STAT4-dependent signalling downstream of the IL-12r has a crucial role in the development of T H 1-cell responses.
Another gene that has been identified as a common risk factor for multiple immune-mediated diseases, including rheumatoid arthritis, is the gene encoding protein tyrosine phosphatase, non-receptor type 22 (PTPN22), which regulates signalling from the TCr and is important for dampening the activation signals initiated following TCr ligation. The involvement of PTPN22 in multiple autoimmune diseases places this gene in the company of general autoimmunity genes such as cytotoxic T-lymphocyte antigen 4 (CTLA4) and MHC alleles 64 (BOX 3; TABLE 1). Taken together, the genes that were first discovered by either targeted or GWA approaches support the idea that T-cell signalling pathways have a dominant role in determining susceptibility to rheumatoid arthritis (FIG. 2a) .
Box 3 | The use of human cells to validate functional implications of polymorphisms
One of the main challenges ahead is to identify the functional consequences of the associated polymorphisms that are identified by genome-wide association studies. An elegant example of how this has been accomplished is that of the protein tyrosine phosphatase, non-receptor type 22 (PTPN22) gene that has been associated with susceptibility to rheumatoid arthritis, systemic lupus erythematosus, Grave's disease and type 1 diabetes 86 . PTPN22 encodes a phosphatase that is involved in T-cell receptor (TCR) signalling. Specifically, TCR activation initiates a complex intracellular signalling programme that offers both great sensitivity to antigen and multiple levels of regulatory control over the response to antigen. Following engagement of the TCR complex, protein tyrosine kinases become activated and then phosphorylate immunoreceptor tyrosine-based activation motifs (ITAMs) in the cytoplasmic tails of TCR-CD3 chains. Phosphatases in turn dampen this response, providing a means of turning signalling on and off. The genetic variant associated with autoimmunity is a nucleotide change that results in a single amino-acid substitution from arginine to tryptophan at position 620 (R620W). To gain insight into the function of PTPN22 in autoimmunity, Rieck and colleagues investigated the function of lymphocytes isolated from patients who are heterozygous or homozygous for the R620W variant 87 . Patients homozygous for the R620W variant showed a marked defect in T-cell responses to antigen stimulation, and heterozygosity was associated with decreased responsiveness of memory CD4 + T cells following TCR stimulation. Decreased receptor-mediated signals could impair normal T-cell selection and result in the survival of a population of autoreactive lymphocytes, or loss of the regulatory mechanisms by which such cells are normally held in check. This study underscores the importance of studying genetic variants within an affected population to yield data relevant to gene function in the context of the disease. Systemic lupus erythematosus. The first quarter of 2008 has witnessed a large increase in the number of genetic discoveries for SLE as a result of the use of GWA studies. SLE is a prototypical, multisystem autoimmune disease that mainly affects women of child-bearing age and is usually characterized by the loss of tolerance to nuclear antigens and the production of autoantibodies. The STAT4 and PTPN22 genes that had previously been identified as risk factors for SLE through targeted association studies were also identified in GWA studies of patients with SLE 63, 65 (TABLE 1) . The discovery of several other SLE-specific risk factors by recent GWA studies and additional targeted studies provides compelling evidence that variation in genes with key functions in the adaptive immune system is involved in the pathogenesis of the disease 17, 25, [66] [67] [68] (FIG. 2b) .
Similar to some other autoimmune diseases, alleles of the antigen-presenting MHC class II proteins have long been associated with the risk of SLE 69 . Gene expression studies and analysis of plasma cytokine profiles of patients with the disease have previously shown a strong link between SLE pathogenesis and type I IFN signalling 70, 71 . Therefore, the discovery of SNPs that affected alternative splicing and altered steady-state levels of IrF5 (a component of the type I IFN signalling pathway) in patients with SLE was an important advance 72 .
Although not all of the recent findings that were reported at the beginning of 2008 have been found to be functionally significant, the identification of ITGAM (integrin α M , also known as complement-receptor type 3 α-subunit) as a susceptibility gene might provide clues as to how impaired clearance of immune complexes affects the pathogenesis of SLE. Previous studies have shown that ITGAM is important for the adherence of neutrophils and monocytes to inflamed endothelium and for the phagocytosis of complementcoated particles 72, 73 . Therefore, ITGAM might have a role in the recruitment of innate immune cells and in the clearance of immune complexes, the latter being a process that is thought to be impaired in a subset of patients with SLE.
Finally, the identification of the association of B-cell scaffold protein with ankyrin repeats 1 (BANK1) with risk of SLE provides a new entry point for the study of B cells in SLE, a cell population that has long been known to be involved in the pathogenesis of the disease. Earlier studies showed that BANK1 deficiency in mice resulted in a hyperactive B-cell phenotype through increased CD40-mediated AKT activation 75 , which is potentially one of the key pathways for the production of autoantibodies. Despite the fact that the current picture of how these genes contribute to SLE is still incomplete (FIG. 2b) , it is becoming clear that an understanding of the common and disease-specific risk factors will be crucial for the appropriate design of targeted therapies. For example, one could envisage an SLE-specific therapeutic approach that aims to deplete hyperactive B cells by targeting BANK1-related signalling pathways, thereby influencing autoantibody production and the regulation of adaptive immune responses.
In addition, rheumatoid arthritis-associated genes, including STAT4 and the TRAF1-C5 locus, are also associated with SLE 22, 62 . However, our understanding of the mechanism of action of these genetic variants is substantially incomplete. The lack of an identified coding variant and/or knockout phenotype indicate that these variants might control protein expression level or function. STAT4-dependent signalling downstream of the IL-12r has a crucial role in the development of T H 1-cell responses 76 . Based on these results, it is tempting to speculate that STAT4 polymorphisms associated with rheumatoid arthritis and SLE could result in increased IL-12-driven signalling, increased IFNg levels and persistent inflammation.
Challenges ahead
We hope that the information presented in the previous sections has convinced the reader that GWA studies have truly revolutionized our ability to catalogue the genetic risk factors involved in many immune-mediated diseases in humans. Despite these successes, there is no doubt that these discoveries are only the tip of the iceberg: the genes that have been identified so far can only account for a minor portion of the overall genetic component of disease risk. Moreover, given that these discoveries have mainly emerged over the past 18 months, there is still much to learn regarding the function of the associated genetic risk variants, and the mechanistic framework presented in this review is by necessity incomplete and can only be considered a starting point. Going forward, there are three main challenges:
Obtain a comprehensive picture of genetic risk. As summarized in TABLE 1, the risk conferred by any individual associated variant is very modest. Even taken together, the set of risk factors discovered so far can account for less than 10% of the overall genetic risk. Why have the GWA studies carried out so far not identified all of the contributing factors? one reason is that these studies have had a small sample size; cohorts in the tens of thousands are needed to have sufficient power to detect the majority of real but modest genetic effects 10, 11 . Although such numbers seem daunting, they are feasible considering the sample sizes of some large international multicentre clinical trials. Alternatively, combining individual association studies to obtain large sample sizes is greatly simplified by the fact that the current genotyping platforms have relatively fixed content and, in fact, recent meta-analyses of GWA studies have proven successful 27, [77] [78] [79] . Another reason that many risk factors remain unknown is that, for a large number of genes that have been discovered, many of the causal variants have not yet been identified. As such, the associated variants identified in the GWA studies might only be imperfectly correlated with the causal variants and, therefore, their genetic effect on disease susceptibility might be underestimated. The identification of causal variants will probably require re-sequencing efforts of large sample sizes, as some genes for which we have already identified a causal variant probably contain additional as-yet-unidentified causal variants.
Finally, one other important reason why the data acquired so far have not provided a comprehensive picture of genetic risk is that the entire genome has not yet been studied by these GWA approaches. other types of polymorphisms, which might include polymorphisms in copy number, mrNA precursors or repeat elements, could also contribute to genomic variation and human disease, an example of which has recently been shown for psoriasis 80 . Clearly, a combination of approaches will be necessary to complete this picture.
Develop an understanding of disease mechanisms. one of the main roles that the field of immunology will have in the coming years in determining the underlying mechanisms of disease susceptibility and progression will be to place the genetic findings of association studies into a functional context. Success in this area will probably require a slight shift in the approaches that immunologists and geneticists currently use when working together. For example, given the significant success of human GWA studies, it is likely that the study of gene function using animal models of disease (such as knock-in and knockout models) will have a predominant role over the use of animals for the identification of disease genes. The main shift, however, will need to come from an integrated approach that allows the study of gene function and from an emphasis on the study of the causal and protective variants identified in the human studies (see BOX 3 for an example). The success of these approaches Nature Reviews | Immunology Crohn's disease
Knock-in and knockout models
Animal models generated through molecular biology experiments that aim to delete the expression of endogenous genes (knock-out) or to introduce a specific allele of a given gene (knock-in).
will depend on our ability to access live cells and tissue specimens from genetically defined individuals and to develop high-throughput functional assays to understand the biological pathways identified. In addition, it will be necessary to combine data from disparate sources to obtain a more global picture of the biological networks that are perturbed by the causal variants (FIG. 3) . Several such integrated pathway and network approaches are emerging that will increase our understanding of the fundamentals of disease pathogenesis [81] [82] [83] [84] [85] .
Translate findings into medical practice. These discoveries must eventually be applied to clinical practice to have a practical impact on society. A GWA-studyderived information-driven approach has the potential to shift the emphasis away from symptom control and alleviation towards targeting of the proximal causal factors in disease, which would be an important victory for medicine. Immune-mediated diseases have the greatest potential for successful treatment given our ability to readily access, assess and modulate components of the immune system. . c | Microarray analysis of peripheral blood and intestinal biopsy samples from Crohn's disease patients is used to examine changes in gene expression that are associated with identified causal variants. d | Analysis of functional protein domains surrounding causal variants can reveal more information about the role of disease-associated genes; for example, association of nucleotide-binding oligomerization domain protein 2 (NOD2) and leucine-rich repeat (LRR) domains, which are involved in sensing breakdown products of microorganisms or damaged cells, indicates that alterations in these processes might contribute to disease pathology 87 . e | Bioinformatics approaches are applied to find interactions between pathways that involve disease-associated proteins. f | Genetic manipulation of model organisms, such as zebrafish and nematode worms, can be used to elucidate microorganism-host cell interactions that may be influenced by the candidate genes and may influence susceptibility to Crohn's disease. The short life-cycle and the ability to rapidly modify these organisms at the genetic level offer some advantages over mouse models. It is important to consider that some associated variants predispose to disease, whereas others are protective. The existence of both predisposing and protective alleles in a single molecule (for example, the Crohn's-diseaseassociated variants in IL23R) illustrates that a meticulous and comprehensive understanding of the mechanisms involved in disease pathogenesis is required to develop safe and effective therapeutics. Finally, although no single causal variant is likely to have any diagnostic value owing to the modest risk conferred by each individual allele, a more immediate payoff could be the development of comprehensive risk models that would incorporate an individual' s current immune status and genetic and non-genetic risk factors to provide the necessary tools (such as biomarkers and predictive algorithms) to aid in clinical management.
In conclusion, although the initial GWA studies have only identified a small proportion of the entire set of genetic risk factors for common immune-mediated diseases, they have already had a significant impact on our understanding of several of the key biological pathways that are involved in disease pathogenesis. The path forward for the further identification of additional genetic risk factors relies largely on our ability to study much larger cohorts of well-phenotyped patients. The greatest challenges ahead will be the integration of genetic knowledge and immunological studies, as well as the eventual application of this new knowledge to improving current clinical treatment options and to the management of patients with these debilitating immune-mediated disorders.
